Given its drying abilities, ophthalmologists often reserve the agent for their more treatment-resistant nAMD and DME patients, while others report a hesitancy to initiate more novel agents; often relegating use to later-lines of therapy.

Source: https://www.prnewswire.com/news-releases/genentechs-vabysmo-well-received-amongst-ophthalmologists-but-use-continues-to-lag-the-competition-according-to-spherix-global-insights-301785097.html